Foreign Corrupt Practices Act Raises Disclosure Dilemma For Internal Investigations
This article was originally published in PharmAsia News
Executive Summary
While companies are feeling pressure to voluntarily disclose potential violations of the U.S. Foreign Corrupt Practices Act, it may not always be the most prudent action, former government attorneys suggested at a recent meeting